HIV/AIDS specialist ViiV Healthcare has again come out as having the best corporate reputation out of 37 pharmaceutical companies, according to a poll of 1,150 patient groups.

The latest annual survey from PatientView puts ViiV, a joint venture between GlaxoSmithKline, Pfizer and Shionogi, on top of the pile for the third year in a row. In joint second were AbbVie and Novo Nordisk, followed by Novartis then Lundbeck and Roche in joint fifth.

The rest of the top 10 is made up of Pfizer, Janssen, UCB and Eisai. Gilead Sciences fell to 14th from second last year.

ViiV came top in four of six categories – patient centricity, patient information, safety and useful products - while Novo was seen as the most transparent. AbbVie scored highest for integrity.

The corporate reputation of the pharma industry as a whole improved in 2014, at the expense of the health insurance sector, but PatientView noted that it still remains lower than that of retail pharmacists and medical device companies.

The report also notes that pricing “is still the most contentious issue from the patient perspective”. Only 14% of patient groups believe pharma is ‘excellent’ or ‘good’ in costing its therapies.